Abstract
The crystal and molecular structures and absolute configuration of (-)-halofantrine hydrochloride were determined by X-ray diffraction. The absolute configuration of the single chiral center of (-)-halofantrine was established to be in the S configuration. Thus, (+)-halofantrine, the more cardiotoxic isomer, has the R configuration. The carbon atom adjacent to the aromatic ring has the same configuration in both (+)- halofantrine and quinidine, suggesting a stereospecific component to the cardiotoxicity produced by both agents. The intramolecular N ... O distance is 4.177 +/- 0.006 A (1 A = 0.1 nm), which is close to the N ... O distance found in the crystal structure of (+/-)-halofantrine hydrochloride, even though the N-H group points in opposite directions in racemic halofantrine and (-)-halofantrine. Both the hydroxyl group and the amine group form hydrogen bonds with the chloride anions. The crystallographic parameters for (-)-halofantrine hydrochloride were as follows: chemical formula, C26H31Cl2F6NO+. Cl-; Mr, 492.4; symmetry of unit cell, orthorhombic; space group, P2(1)2(1)2(1); parameters of unit cell, a was 6.290 +/- 0.001 A, b was 13.533 +/- 0.003 A, and c was 30.936 +/- 0.006 A; volume of the unit cell, 2,633.2 +/- 0.7 A(3); number of molecules per unit cell, 4; calculated density, 1.354 g cm(-3); source of radiation, Cu K(alpha) (lambda = 1.54178 A); mu (absorption coefficient), 3.50 mm(-1); F(000) (sum of atomic scattering factors at zero scattering angle), 1,120; room temperature was used; final R (residual index), 4.75% for 2,988 reflections, with absolute value of Fo > 3sigma(F), where Fo is the observed structure factor and F is the structure factor.
Full Text
The Full Text of this article is available as a PDF (224.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Basco L. K., Gillotin C., Gimenez F., Farinotti R., Le Bras J. In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum. Br J Clin Pharmacol. 1992 May;33(5):517–520. doi: 10.1111/j.1365-2125.1992.tb04081.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Boudreau E. F., Pang L. W., Dixon K. E., Webster H. K., Pavanand K., Tosingha L., Somutsakorn P., Canfield C. J. Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand. Bull World Health Organ. 1988;66(2):227–235. [PMC free article] [PubMed] [Google Scholar]
- Bryson H. M., Goa K. L. Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992 Feb;43(2):236–258. doi: 10.2165/00003495-199243020-00009. [DOI] [PubMed] [Google Scholar]
- Carroll F. I., Berrang B., Linn C. P. Resolution of antimalarial agents via complex formation with alpha-(2,4,5,7-tetranitro-9-fluorenylideneaminooxy) propionic acid. J Med Chem. 1978 Apr;21(4):326–330. doi: 10.1021/jm00202a002. [DOI] [PubMed] [Google Scholar]
- Gimenez F., Gillotin C., Basco L. K., Bouchaud O., Aubry A. F., Wainer I. W., Le Bras J., Farinotti R. Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. Eur J Clin Pharmacol. 1994;46(6):561–562. doi: 10.1007/BF00196116. [DOI] [PubMed] [Google Scholar]
- Karbwang J., Na Bangchang K. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet. 1994 Aug;27(2):104–119. doi: 10.2165/00003088-199427020-00003. [DOI] [PubMed] [Google Scholar]
- Karle I. L., Karle J. Anomalous dispersion of sulfur in quinidine sulfate, (C(20)H(25)N(2)O(2))(2)SO(4).2H(2)O: Implications for structure analysis. Proc Natl Acad Sci U S A. 1981 Oct;78(10):5938–5941. doi: 10.1073/pnas.78.10.5938. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Karle J. M., Karle I. L. Structure of the antimalarial halofantrine hydrochloride. Acta Crystallogr C. 1989 Aug 15;45(Pt 8):1248–1250. doi: 10.1107/s0108270189002210. [DOI] [PubMed] [Google Scholar]
- Karle J. M., Olmeda R., Gerena L., Milhous W. K. Plasmodium falciparum: role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents. Exp Parasitol. 1993 Jun;76(4):345–351. doi: 10.1006/expr.1993.1042. [DOI] [PubMed] [Google Scholar]
- Terefe H., Blaschke G. Direct determination of the enantiomers of halofantrine and its pharmacologically active metabolite N-desbutylhalofantrine by high-performance liquid chromatography. J Chromatogr. 1993 Jun 2;615(2):347–351. doi: 10.1016/0378-4347(93)80352-5. [DOI] [PubMed] [Google Scholar]
- Terefe H., Blaschke G. Direct determination of the enantiomers of the antimalarial drug halofantrine and its active metabolite N-desbutylhalofantrine in human plasma. J Chromatogr B Biomed Appl. 1994 Jul 1;657(1):238–242. doi: 10.1016/0378-4347(94)80094-4. [DOI] [PubMed] [Google Scholar]
- Touze J. E., Bernard J., Keundjian A., Imbert P., Viguier A., Chaudet H., Doury J. C. Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. Am J Trop Med Hyg. 1996 Mar;54(3):225–228. doi: 10.4269/ajtmh.1996.54.225. [DOI] [PubMed] [Google Scholar]
- Watt G., Loesuttiviboon L., Jongsakul K., Shanks G. D., Ohrt C. K., Karnasuta C., Schuster B., Fleckenstein L. Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. Am J Trop Med Hyg. 1994 Feb;50(2):187–192. doi: 10.4269/ajtmh.1994.50.187. [DOI] [PubMed] [Google Scholar]
- Wesche D. L., Black J. A comparison of the antimalarial activity of the cinchona alkaloids against Plasmodium falciparum in vitro. J Trop Med Hyg. 1990 Jun;93(3):153–159. [PubMed] [Google Scholar]
- ter Kuile F. O., Dolan G., Nosten F., Edstein M. D., Luxemburger C., Phaipun L., Chongsuphajaisiddhi T., Webster H. K., White N. J. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet. 1993 Apr 24;341(8852):1044–1049. doi: 10.1016/0140-6736(93)92409-m. [DOI] [PubMed] [Google Scholar]